$Kite Pharma(KITE)$ Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel
First Investigational CAR-T Therapy to Demonstrate Positive Data in Aggressive Non-Hodgkin Lymphoma (NHL) Biologics License Application Submission Based on the Primary Analysis of the ZUMA-1 Phase 2 Trial Prescription Drug User Fee Act (PDUFA) Set for November 29, 2017